{
    "xml": "<topic id=\"PHP1463\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/tinzaparin-sodium\" basename=\"tinzaparin-sodium\" title=\"TINZAPARIN SODIUM\">\n<title>TINZAPARIN SODIUM</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_228\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/heparins/tinzaparin\">Tinzaparin</xref>\n</p>\n<data name=\"vtmid\">350469004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_502671253\" title=\"Heparins\">Heparins</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34597\" title=\"HEPARINS\" namespace=\"/drug-classes/heparins\">HEPARINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP34745\" outputclass=\"unlicensedUse\" rev=\"1.9\" parent=\"/drugs/tinzaparin-sodium\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Not licensed for the treatment of venous thromboembolism in pregnancy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34759\" outputclass=\"sideEffects\" rev=\"1.7\" parent=\"/drugs/tinzaparin-sodium\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Headache</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34771\" outputclass=\"pregnancy\" parent=\"/drugs/tinzaparin-sodium\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Not known to be harmful, low molecular weight heparins do not cross the placenta.</p>\n<p>Vials contain benzyl alcohol&#8212;manufacturer advises avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34803\" outputclass=\"breastFeeding\" parent=\"/drugs/tinzaparin-sodium\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Due to the relatively high molecular weight of tinzaparin and inactivation in the gastro-intestinal tract, passage into breast-milk and absorption by the nursing infant are likely to be negligible; however manufacturer advise avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34765\" outputclass=\"renalImpairment\" parent=\"/drugs/tinzaparin-sodium\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Manufacturer advises caution if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Risk of bleeding may be increased.</p>\n<p>Unfractionated heparin may be preferable.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInRenalImpairment\">\n<sectiondiv>\n<p>In renal impairment monitoring of anti-Factor Xa may be required if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2.</sup>\n</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP34735\" outputclass=\"monitoringRequirements\" parent=\"/drugs/tinzaparin-sodium\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Routine monitoring of anti-Factor Xa activity is not usually required during treatment with tinzaparin, but may be necessary in patients at increased risk of bleeding (e.g. in renal impairment and those who are underweight or overweight).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1463-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/tinzaparin-sodium\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77407\" title=\"Solution for injection\" namespace=\"/drugs/tinzaparin-sodium/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78403\" namespace=\"/treatment-summaries/venous-thromboembolism\" title=\"Venous thromboembolism\" count=\"1\" rel=\"backlink\">Venous thromboembolism</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78413\" namespace=\"/treatment-summaries/parenteral-anticoagulants\" title=\"Parenteral anticoagulants\" count=\"2\" rel=\"backlink\">Parenteral anticoagulants</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_228\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/heparins/tinzaparin\" title=\"Tinzaparin\" count=\"1\" rel=\"link\">Tinzaparin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34597\" namespace=\"/drug-classes/heparins\" title=\"HEPARINS\" count=\"1\" rel=\"link\">HEPARINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77407\" namespace=\"/drugs/tinzaparin-sodium/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP1463",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/tinzaparin-sodium",
    "basename": "tinzaparin-sodium",
    "title": "TINZAPARIN SODIUM",
    "interactants": [
        {
            "id": "bnf_int_228",
            "label": "Tinzaparin"
        }
    ],
    "vtmid": "350469004",
    "drugClassification": [
        "Heparins"
    ],
    "inheritsFromClass": [
        "HEPARINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Not licensed for the treatment of venous thromboembolism in pregnancy.",
                "html": "<p>Not licensed for the treatment of venous thromboembolism in pregnancy.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Headache",
                        "html": "Headache",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Not known to be harmful, low molecular weight heparins do not cross the placenta.\n\nVials contain benzyl alcohol&#8212;manufacturer advises avoid.",
                "html": "<p>Not known to be harmful, low molecular weight heparins do not cross the placenta.</p><p>Vials contain benzyl alcohol&#8212;manufacturer advises avoid.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Due to the relatively high molecular weight of tinzaparin and inactivation in the gastro-intestinal tract, passage into breast-milk and absorption by the nursing infant are likely to be negligible; however manufacturer advise avoid.",
                "html": "<p>Due to the relatively high molecular weight of tinzaparin and inactivation in the gastro-intestinal tract, passage into breast-milk and absorption by the nursing infant are likely to be negligible; however manufacturer advise avoid.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Manufacturer advises caution if eGFR less than 30 mL/minute/1.73 m2.",
                "html": "<p>Manufacturer advises caution if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Risk of bleeding may be increased.\n\nUnfractionated heparin may be preferable.",
                "html": "<p>Risk of bleeding may be increased.</p><p>Unfractionated heparin may be preferable.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "In renal impairment monitoring of anti-Factor Xa may be required if eGFR less than 30 mL/minute/1.73 m2.",
                "html": "<p>In renal impairment monitoring of anti-Factor Xa may be required if eGFR less than 30&#8239;mL/minute/1.73&#8239;m<sup>2.</sup>\n</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Routine monitoring of anti-Factor Xa activity is not usually required during treatment with tinzaparin, but may be necessary in patients at increased risk of bleeding (e.g. in renal impairment and those who are underweight or overweight).",
                "html": "<p>Routine monitoring of anti-Factor Xa activity is not usually required during treatment with tinzaparin, but may be necessary in patients at increased risk of bleeding (e.g. in renal impairment and those who are underweight or overweight).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77407",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78403",
                "label": "Venous thromboembolism",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78413",
                "label": "Parenteral anticoagulants",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_228",
                "label": "Tinzaparin",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34597",
                "label": "HEPARINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77407",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}